Metformin does not reduce inflammation in diabetics with abdominal aortic aneurysm or at high risk of abdominal aortic aneurysm formation by Wang, S. Keisin et al.
Metformin does not Reduce Inflammation in Diabetics with AAA or at High Risk of AAA 
Formation 
S. Keisin Wang, Linden A. Green, Ashley R. Gutwein, Bianca Kenyon, Raghu L. Motaganahalli, Andres
Fajardo, Alok K. Gupta, Michael P. Murphy 
Introduction: 
The protective effect of diabetes mellitus (DM) on abdominal aortic aneurysm (AAA) formation 
and growth has been repeatedly observed in population studies but continues to be poorly understood.  
However, recent investigations have suggested that metformin, a staple antihyperglycemic medication, 
may be independently protective against AAA formation and growth.  Therefore, we describe the effect 
of metformin in AAA and at-risk patients on markers of inflammation, the driver of early AAA formation 
and growth. 
Methods: 
Peripheral blood was collected from patients previously diagnosed with AAA or presenting for 
their U.S. Preventive Task Force- recommended (USPTF) AAA screening.  Plasma and circulating 
peripheral blood mononuclear cells (PBMCs) were isolated using ficoll density centrifugation.  
Circulating plasma inflammatory and regulatory cytokines were assessed with enzyme-linked 
immunosorbent assays (ELISA).  CD4+ cell phenotyping was performed using flow cytometric analysis 
and expressed as a proportion of total CD4+ cells.  To determine the circulating antibody to self-antigen 
response, a modified ELISA was performed against antibodies to collagen type V (COLV) and elastin 
fragments (ELNf). 
Results: 
Peripheral blood was isolated from 266 patients without DM (n=182), with DM not treated with 
metformin (n=34), and with DM actively taking metformin (n=50) from 2015-2017.  We found no 
differences in the expression of Tr1, Th17, and Treg CD4+ fractions within diabetics ± metformin.  When 
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comparing inflammatory cytokines, we detected no differences in IL-1β, IL-6, IL-17, IL-23, IFN-γ, and 
TNF-α.  Conversely, no differences were observed pertaining to the expression to regulatory cytokines 
IL-4, IL-10, IL-13, TSG-6, or TGF-β.  Lastly, no differences in expression of COLV and ELNf antigen 
and/or antibodies were detected with metformin use in diabetics.     
 
Conclusion: 
Metformin in diabetics at-risk for AAA or diagnosed with AAA does not seem to alter the 
peripheral inflammatory environment.   
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 Background 
 
 AAA is an major source of morbidity and mortality in the Western Hemisphere affecting as many 
as 4% of men starting their sixth decade of life.(1)  This pathology is characterized by early local 
inflammation causing degradation of the arterial wall and progressive dilation until increasing wall 
tension eventually results in rupture.(2-4)  Of those experiencing a catastrophic rupture event, 
approximately half die immediately and never present to the hospital; overall, short-term rupture mortality 
approaches 80%.(5, 6)  In the United States alone, over 15,000 deaths per annum are directly related to 
AAA rupture making it the number 11 killer of Americans.(7)   
 
The gold standard of AAA care continues to be rupture prevention via aneurysm resection and 
aortic reconstruction when cross-sectional diameter exceeds 5.5 cm.(8)  As a result, over 40,000 highly-
morbid aortic reconstructions are performed annually resulting in health care costs in excess of $116,000 
per case in the perioperative period.(9, 10)  Therefore, the magic bullet for AAA continues to be the 
elusive pharmaceutical which can slow or stop diameter growth. 
 
Previous population studies have suggested a protective effect of DM on AAA formation and 
growth.(6, 11-13)  Only recently has metformin been implicated as a potential cause of the AAA-
privileged nature of the diabetic patient.(14, 15)  Our group has previously published studies suggesting 
the existence of an antigen-specific response unique to AAA subjects to breakdown products of elastin 
and collagen which may drive both immune aberrations leading to faulty regulation, via Tr1 and Treg 
dysfunction, and runaway inflammation, via Th17 overexpression.(16-19)  Therefore, the purpose of this 
investigation was to establish the presence of cytokine changes, if any, in a population of AAA and high-
risk patients associated with metformin use which may explain the potentially protective effect of 
metformin.     
 Methods 
 
Blood Banking and Isolation of PBMCs and Plasma 
  
 After the appropriate approval was obtained from the Indiana University (IU) Institutional 
Review Board (IRB #1408881234), peripheral blood was collected from individuals giving informed 
consent at IU School of Medicine affiliated hospitals from 2015 to 2017.  AAA-positive samples (>30 
mm) were collected from individuals presenting for follow-up of previously diagnosed aneurysms while 
samples from at-risk subjects (risk-factor matched, RFM) were isolated from patients who screened 
negative for their USPTF recommended AAA ultrasounds at age 65.(20)  Mononuclear cells were 
isolated by standard ficoll density separation using Accuspin tubes (Sigma) as described in detail 
elsewhere.(17)  Isolated PBMCs and plasma were stored at -80 °C in small aliquots to minimize 
freeze/thaw cycles.   
 
CD4+ Lymphocyte Phenotyping 
 
 Cell staining using antibodies against identifying surface markers to Tr1, Th17, and Treg subsets 
of CD4+ lymphocytes were performed per manufacturer’s instructions (1:10, Miltenyi) unless otherwise 
noted.  Tr1: CD4-FITC, CD49b-PE (1:20), LAG3-APC (1:20); Treg: CD4-FITC, CD25-PE, FOXP3-
APC; Th17: CD4-FITC, CD194-PE, CD196-APC.  Tr1 lymphocytes were stained for 15 minutes at room 
temperature while the remaining subsets were stained for 10 minutes at 4 °C.  Flow cytometric analysis 
was performed on an Accuri C6 (BD) with CellQuest software (BD). 
 
Plasma Cytokine and Antigen Quantification 
 
 Cytokine concentration in the plasma was determined using commercially available ELISA kits 
and performed per manufacturer’s recommendations.  Kits, when available, were obtained from R&D; if 
a cytokine kit was not available via R&D, an alternative was sourced from Sigma.  To calculate absolute 
plasma concentrations, absorbance was read with a Cytation 5 (Biotek) at 450 nm and referenced to a 
standard curve.  
 
Plasma Antibody Quantification 
  
 A modified ELISA was performed to determine relative concentrations of antibodies specific to 
COLV and ELNf.  Human COLV (Sigma) and Elastin (Elastin Products Company) peptides were 
dissolved in phosphate buffered saline to a stock working solution of 25 ug/mL.  This solution was used 
to coat a high protein binding 96-well polystyrene plate (Sigma) overnight at 4 °C.  A blocking step was 
performed with a solution of 1% BSA for 2 hours at 37 °C or overnight at 4 °C.  Plasma samples were 
sequentially diluted up to 1:1000 to determine optimal concentration and incubated for 2 hours at room 
temperature.  A goat anti-human IgG Fc antibody conjugated to horseradish peroxidase (HRP, Sigma) 
was utilized as a secondary antibody per manufacturer’s recommended dilution.  Reactions were 
performed using a 1-step TMB turbo substrate (Sigma) for 30 minutes before a 1 M sulfuric acid stop 
solution was added.  Absorbance was measured at 450 nm to determine relative intensity.(21)      
 Results 
 
Baseline Comorbidities and Medications 
 
 From June 2015 to September of 2017, a total of 266 patients contributed blood to the 
biorepository utilized for this study.  All patients, regardless of AAA status, were divided into three 
cohorts, 1) no DM (n=182), 2) DM without metformin (n=34), and 3) DM with metformin (n=50).  The 
baseline comorbidities of these cohorts are detailed in table 1.  We observed no difference with respect to 
age between cohorts (p=0.98).  In terms of Framingham Risk Scores, nondiabetics had the lowest risk 
(33.1%) compared to a higher risk associated with DM regardless of metformin use (49.4% vs 49.8%).  
Our three cohorts were homogeneous in terms of AAA, chronic obstructive pulmonary disease (COPD), 
hyperlipidemia (HLD), coronary artery disease (CAD), and AAA familial history (FHx) incidence.  
However, heterogeneity was encountered with respect to the incidence of hypertension (HTN), peripheral 
arterial disease (PAD), chronic kidney disease (CKD), and obesity (BMI >30).  Baseline medication 
profiles are described in detail in table 2.  Although a significant difference in the usage of angiotensin-
receptor blockers (ARB) was noted, this effect disappeared when the prevalence of angiotensin-
converting enzyme inhibitors (ACEi) were combined.  Except for aspirin use, medication homogeneity 
was encountered across all cohorts.    
 
CD4+Lymphocyte Subsets 
  
 CD4+ lymphocytes of interest consisted of the regulatory Tr1 and Treg fractions and the 
inflammatory Th17 phenotype.  We previously noted that patients with AAA demonstrated significantly 
decreased expression of the regulatory Tr1 (7.3% vs 1.4%, p<0.01) and Treg (2.6% vs 1.5%, p=0.05) 
lymphocytes compared to their RFM counterparts.(4, 17)  Additionally, a strong trend suggesting an 
increase in the expression of the inflammatory Th17 cell was observed in the patients diagnosed with 
AAA.  Therefore, we investigated whether the expression of these cell types normalized with the presence 
of metformin.  In the diabetics, we did not observe a change in the Tr1 (3.0% vs 5.0%, p=0.24), Th17 
(3.0% vs 2.9%, p=0.92), or Treg (1.6% vs 1.2%, p=0.47) fractions with the presence of metformin which 
would suggest a beneficial effect on decreasing inflammation (Figure 1).     
 
Inflammatory Cytokines 
  
 The effect of metformin on the inflammatory cytokines OPN, IL-1β, IL-6, IL-17, IFN-γ, TNF-α, 
and IL-23 were examined.  The presence of DM did not seem to significantly alter the inflammatory 
environment compared to nondiabetics.  Although weak trends towards decreased concentrations of OPN 
(9.1 vs 6.3 ng/mL, p=0.34), IL-1β (4.4 vs 3.9 ng/mL, p=0.45), and IFN-γ (18.4 vs 9.2 ng/mL, p=0.24) 
were seen, no statistically significant reduction in inflammatory cytokines were confirmed with the 
introduction of metformin to diabetics (Figure 2).   
 
Regulatory Cytokines 
 
 The regulatory cytokines TGF-β, IL-4, IL-10, IL-13, and TSG-6 were used as markers of 
inflammation suppression (Figure 3).  While IL-4 concentration increased in response to metformin (2.7 
vs 5.1 ng/mL), this did not reach statistical significance (p=0.23).  In the remaining regulatory cytokines 
examined, no trends were noted to suggest an antiinflammatory effect of metformin in diabetics taking 
metformin.     
 
COLV and ELNf Antigen and Antibody  
  
 In our previous experiments, we noted significantly higher concentrations of both ELNf/COLV 
antigen and antibodies in circulation of RFM and AAA patients compared to healthy controls.  However, 
we did not observe an inflammation suppressing effect of metformin on circulating COLV (0.73 vs 0.62 
ng/mL, p=0.56) or ELNf (15.1 vs 14.8 ng/mLs, p=0.94) antigens.  Between all cohorts, plasma antigen 
levels were lowest in the nondiabetic patients.  Similarly, antibodies specific to COLV (0.42 vs 0.38 
Relative Units, p=0.76) and ELNf (0.22 vs 0.20 RUs, p=0.78) did not differ with the introduction of 
metformin.  With respect to both peptides, a slight nonsignificant increase was observed in circulating 
antigens and antibodies with the presence of DM compared to patients without DM.  
 Discussion 
 
 We established the IU Center for Aortic Disease biorepository in 2015 as part of a concerted 
effort to stimulate research into the immune component of AAA formation and growth.  Since the 
beginning of this initiative, we have collected blood from over 330 individuals.  With the assistance of 
this growing collection, multiple anomalies in the human immune response that characterizes the AAA 
condition have been described.(17, 19)  
 
 The negative association between DM and AAA has been observed and noted in numerous 
population-based studies over the previous two decades.(15)  A recent meta-analysis pooled 13 
population, prospective cohort, and case-control studies and reported an odds ratio of 0.59 (95% CI, 0.52 
– 0.67; p<0.01) in support of the protective effect of DM on AAA formation.(22)  Another similar review 
identified 17 large population studies and observed an odds ratio of 0.80 (0.70 – 0.90; p<0.01) between 
DM and AAA once again implicating DM as a protective factor.(12)  It is not clear how DM attenuates 
AAA formation; however, animal models of hyperglycemia have demonstrated evidence of decreased 
infiltration of macrophages, elastolysis, and neovascularization of the aortic wall which are all hallmark 
of early AAA formation.(23)  Additionally, the diabetic environment may also favorably alter vascular 
smooth muscle cell physiology, increase advanced glycation end-products, down-regulate matrix 
metalloproteinases, and decrease fibrinolysis causing an overall increase in aortic structural integrity.(24)   
 
 With the increasing drive to establish a pharmaceutical treatment for AAA, the role of 
medications associated with DM have been scrutinized in detail.(25)  These initial studies supported a 
protective effect of metformin, thiazolidinediones, and sulfonylureas not observed in α-glucosidase and 
DPP-4 inhibitors.(25)  While the effect of thiazolidinediones and sulfonylureas have been called into 
question by some studies claiming little protective effect, metformin seemed to be particularly effective at 
both prevention and progression of AAA across multiple clinical investigations.(14, 26)  It is thought that 
metformin functions to decrease circulating glucose by inhibiting hepatic gluconeogenesis and blunting 
the effect of glucagon via inhibition of mitochondrial complex I and inactivation of the protein kinase A 
(PKA) and cyclic adenosine monophosphate (cAMP) signaling pathway.(27)  This effect also results in 
an increase in overall sensitivity to circulating insulin.  While metformin’s AAA-protective mechanism 
continues to be nebulous, suggestions of a pleiotropic effect consisting of the inhibition of extracellular 
matrix (ECM) remodeling, downregulation of inflammation, and reduction of oxidative stress have been 
made.(14, 28-31)  
 
We did not observe a decrease in inflammation with metformin use in a combined cohort of at-
risk and AAA patients.  However, when the population is divided into AAA and non-AAA patients by 
metformin status, no differences are once again seen with respect to CD4+ lymphocyte, cytokine, antigen, 
and antibody expression.   
 
 We previously reported significant aberrations between the RFM and AAA populations with 
respect to CD4+ fractions of lymphocytes in circulation.(17, 19)  In particular, there is a depletion of the 
Tr1 (CD4+LAG3+CD49b+) regulatory lymphocyte in the AAA condition.(17-19)  This inflammation 
suppressing cell is unique in the immune response as it is antigen specific, elaborating the regulatory 
cytokine IL-10 and eliminating myeloid derived antigen-presenting cells via the granzyme B pathway in 
response to antigen recognition and activation to suppress local inflammation.(32)  Not surprisingly, we 
also noted a reduction of circulating IL-10 in AAA patients corresponding to the aforementioned loss of 
Tr1 activity.(17)  In this study, we did not observe an antiinflammatory effect of metformin on IL-10 or 
Tr1 expression towards levels seen in the RFM population.  Additionally, no therapeutic effect was seen 
in the inflammatory Th17 or regulatory Treg population towards “healthy” levels. 
 
 Previous reports suggest that circulating elastin and collagen type V peptides may be significant 
antigens in the pathogenesis of COPD, an inflammatory and destructive disease of the pulmonary system 
and strong risk factor for AAA formation.(21, 33, 34)  In our AAA population, we noted increased 
expression of both soluble elastin antigen and antibodies circulating in the peripheral plasma of AAA 
patients compared to RFM controls.(4)  We believe these two antigens may play a major role in driving 
the self-sensitization of inflammatory immune cells to the native infrarenal aortic wall as they predictably 
increase from healthy, to RFM, and finally AAA-diagnosed subjects.(4)  Once again, our investigation 
did not demonstrate a decrease with metformin in the circulation of these inflammatory peptides in the 
diabetic population. 
 
 Although previous metformin studies suggested a reduction in the rate of AAA formation and 
growth, no benefit was observed with on the risk of AAA rupture.  A recent study from Denmark 
reviewed a national ruptured AAA registry over 15 years starting in the late 1990s (n=362).  In their 
series, 22.4% of ruptures were long-term metformin users (compared to 28.8% of controls).  After 
adjustment for covariates, the OR reported was 0.84 (CI, 0.61 – 1.17) suggesting no effect of metformin 
in the diabetic population at rupture risk reduction.(35)  The authors conclude their findings, in 
conjunction with previous studies establishing the effectiveness of all antidiabetic medications 
equally(36), suggest that DM, rather than metformin, is the overwhelming variable generating protection 
to AAA.  The data presented in this manuscript can be interpreted to provide limited evidence supporting 
that assertion.  However, it is worth noting that with exception to Treg (higher in nondiabetics) and Th17 
expression (lower in diabetics), no differences were noted in the markers reported in this manuscript when 
the RFM cohort was compared to diabetics regardless of metformin status as well.    
 
 
There are several limitations to the results reported in this study.  Because of the design of this 
investigation, a retrospective review of a prospectively maintained database, small numbers of patients 
were included in several of the groups for statistical analysis.  This limits the power, amplifies error, and 
makes conclusions weak.  Additionally, the vast majority of samples in our biorepository was collected 
from patients at our VA medical facility; therefore, nearly 100% of the subjects studied were male further 
limiting the generalizability of the data presented.  
 Conclusion 
 
 Although metformin has been associated with protection against AAA in previous studies, we did 
not observe any alterations in cytokine signaling, CD4+ phenotype expression, or circulating 
antigens/antibodies which would explain this effect.
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